{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:42:57Z","timestamp":1790430177162,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013757","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000}}],"reference-count":127,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013757.pub2","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T07:57:21Z","timestamp":1637049441000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children"],"prefix":"10.1002","volume":"2021","author":[{"given":"Luis","family":"Garegnani","sequence":"additional","affiliation":[{"name":"Associate Cochrane Centre; Instituto Universitario Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Styrmisd\u00f3ttir","sequence":"additional","affiliation":[{"name":"Faculty of Medicine; Lund University; Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Roson Rodriguez","sequence":"additional","affiliation":[{"name":"Research Department; Instituto Universitario Hospital Italiano; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Micaela","family":"Escobar Liquitay","sequence":"additional","affiliation":[{"name":"Central Library; Instituto Universitario Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Esteban","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n INFANT; Buenos Aires Argentina"},{"name":"Pediatric Stepdown Unit; Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan VA","family":"Franco","sequence":"additional","affiliation":[{"name":"Associate Cochrane Centre; Instituto Universitario Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"10.1002\/14651858.CD013757.pub2-BIB0001|cit1","unstructured":"Blanken M Rovers M Molenaar J Winkler-Seinstra P Meijer A Kimpen J Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 \u2013 7; Washington, D.C Pediatric Academic Societies Annual Meeting 2013"},{"issue":"6","key":"10.1002\/14651858.CD013757.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.cct.2012.07.010","article-title":"Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks","volume":"33","author":"Blanken","year":"2012","journal-title":"Contemporary Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00431-017-3046-1","article-title":"Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants","volume":"177","author":"Blanken","year":"2018","journal-title":"European Journal of Pediatrics"},{"issue":"19","key":"10.1002\/14651858.CD013757.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","article-title":"Respiratory syncytial virus and recurrent wheeze in healthy preterm infants","volume":"368","author":"Blanken","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0005|cit5","first-page":"A6127","article-title":"Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life","volume":"187","author":"Bont","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0006|cit6","unstructured":"Effect of palivizumab on respiratory syncytial virus-associated burden of disease \u2013 a randomized controlled trial www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-004105-10\/NL"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0007|cit7","first-page":"OA4939","article-title":"Infant RSV prophylaxis, RSV infection, and nasopharyngeal microbiota at age six years","volume":"54","author":"Man","year":"2019","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD013757.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S2213-2600(19)30470-9","article-title":"Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial","volume":"8","author":"Man","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013757.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S2213-2600(18)30055-9","article-title":"Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial","volume":"6","author":"Scheltema","year":"2018","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0010|cit10","first-page":"PA4999","article-title":"Infant RSV infection changes nasal epithelial DNA methylation at 6 years of age","volume":"54","author":"Xu","year":"2019","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD013757.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","journal-title":"Journal of Pediatrics"},{"issue":"10","key":"10.1002\/14651858.CD013757.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.4161\/hv.29635","article-title":"Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants","volume":"10","author":"Forbes","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD013757.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","author":"The IMpact-RSV Study Group","year":"1998","journal-title":"Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0014|cit14","first-page":"110","article-title":"Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group","volume":"17","author":"Subramanian","year":"1998","journal-title":"Pediatric\u00a0Infectious Disease Journal"},{"issue":"8","key":"10.1002\/14651858.CD013757.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1055\/s-0033-1356485","article-title":"Palivizumab prophylaxis: does It have any influence on the growth and development of the infants?","volume":"31","author":"Tavsu","year":"2014","journal-title":"American Journal of Perinatology"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0016|cit16","unstructured":"Prevention of respiratory syncytial virus infection by monoclonal antibody Deutsche Apotheker\u00a0Zeitung 1999 139 28 36"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0017|cit17","unstructured":"Palivizumab: new indication. Moderate reduction in hospitalisation rate Prescrire\u00a0International 2004 13 74 213 6"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0018|cit18","first-page":"527","article-title":"Synagis: an anti-RSV monoclonal antibody","volume":"25","author":"Driver","year":"1999","journal-title":"Pediatric\u00a0Nursing"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0019|cit19","unstructured":"A study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of MEDI-524, a humanized\u00a0enhanced potency monoclonal antibody against respiratory syncytial virus (RSV), in children with hemodynamically significant congenital heart disease http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2007-002070-61-PL"},{"issue":"3","key":"10.1002\/14651858.CD013757.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/2249-4847.119990","article-title":"Does RSV prophylaxis prevents future recurrent wheeze in preterm infants?","volume":"2","author":"Ignacio","year":"2013","journal-title":"Journal of Clinical Neonatology"},{"issue":"3","key":"10.1002\/14651858.CD013757.pub2-BIB0021|cit21","first-page":"227","article-title":"Palivizumab (Synagis\u00ae) in the prevention of lower respiratory tract infection in children due to respiratory syncytial virus (RSV)","volume":"17","author":"Johnson","year":"1999","journal-title":"Today's Therapeutic Trends"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0022|cit22","first-page":"S39","article-title":"Prophylactic palivizumab prevents respiratory syncytial virus infection in pediatric\u00a0patients with immunodeficiencies","volume":"66","author":"Koganesawa","year":"2019","journal-title":"Pediatric\u00a0Blood & Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013757.pub2-BIB0023|cit23","first-page":"170","article-title":"Prophylaxis against RS virus infection","volume":"99","author":"Naver","year":"2002","journal-title":"L\u00e4kartidningen"},{"issue":"10","key":"10.1002\/14651858.CD013757.pub2-BIB0024|cit24","first-page":"371","article-title":"Prevention of infection by respiratory syncytial virus (VRS) by SYNAGYS\u00ae (PALIVIZUMAB)","volume":"34","author":"Pin","year":"2002","journal-title":"Allergie et Immunologie"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0025|cit25","first-page":"214","article-title":"Children hospitalized with respiratory syncytial virus (RSV) infection after palivizumab prophylaxis in two large paediatric tertiary care centers","volume":"98","author":"Rajakumar","year":"2009","journal-title":"Acta Paediatrica"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"A37","DOI":"10.1136\/adc.2011.212563.80","article-title":"Does RSV infection cause pulmonary hypertension in children undergoing cardiac surgery?","volume":"96","author":"Tulloh","year":"2011","journal-title":"Archives of Disease in Childhood"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0027|cit27","unstructured":"Randomized, multicenter, open-label study on PREvention of respiratory SEquelae of RSV bronchiolitis in preterm babies (PRESERV) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-002980-25\/IT"},{"issue":"Suppl 28","key":"10.1002\/14651858.CD013757.pub2-BIB0028|cit28","first-page":"270S","article-title":"Humanised monoclonal antibody to respiratory syncytial virus (MEDI-493) significantly reduces the incidence of RSV hospitalisation in at-risk infants","volume":"12","author":"Lenney","year":"1998","journal-title":"European Respiratory Journal. Supplement"},{"issue":"3","key":"10.1002\/14651858.CD013757.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"e20182308","DOI":"10.1542\/peds.2018-2308","article-title":"Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial","volume":"143","author":"Alansari","year":"2019","journal-title":"Pediatrics"},{"issue":"7","key":"10.1002\/14651858.CD013757.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00705-019-04247-4","article-title":"Taxonomy of the order mononegavirales: update 2019","volume":"164","author":"Amarasinghe","year":"2019","journal-title":"Archives of Virology"},{"issue":"4","key":"10.1002\/14651858.CD013757.pub2-BIB0031|cit31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006602.pub4","article-title":"Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children","author":"Andabaka","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013757.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/INF.0000000000001533","article-title":"Effectiveness of palivizumab in high-risk infants and children: a propensity score weighted regression analysis","volume":"36","author":"Anderson","year":"2017","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"9","key":"10.1002\/14651858.CD013757.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/0009922808320699","article-title":"Chronological and clinical characteristics of apnea associated with respiratory syncytial virus infection: a retrospective case series","volume":"47","author":"Arms","year":"2008","journal-title":"Clinical Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/jpids\/piz087","article-title":"Estimated burden of community-onset respiratory syncytial virus associated hospitalizations among children aged <2 years in the United States, 2014-15","volume":"9","author":"Arriola","year":"2019","journal-title":"Journal of the Pediatric Infectious Diseases Society"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"GRADE Working Group","year":"2004","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD013757.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/occmed\/kqm110","article-title":"Active and passive immunity, vaccine types, excipients and licensing","volume":"57","author":"Baxter","year":"2007","journal-title":"Occupational Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013757.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40121-016-0123-0","article-title":"Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in Western countries","volume":"5","author":"Bont","year":"2016","journal-title":"Infectious Diseases and Therapy"},{"issue":"6","key":"10.1002\/14651858.CD013757.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1067\/mpd.2000.110531","article-title":"Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid","volume":"137","author":"Boyce","year":"2000","journal-title":"Journal of Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1542\/peds.2014-1665","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"134","author":"Brady","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD013757.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/infdis\/jiy517","article-title":"Mortality associated with acute respiratory infections among children at home","volume":"219","author":"Caballero","year":"2019","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13052-017-0390-8","article-title":"The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence","volume":"43","author":"Capizzi","year":"2017","journal-title":"Italian Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1542\/peds.2008-1036","article-title":"Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial","volume":"125","author":"Carbonell-Estrany","year":"2010","journal-title":"Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD013757.pub2-BIB0043|cit43","first-page":"281","article-title":"Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization","volume":"66","author":"Chanock","year":"1957","journal-title":"American Journal of Hygiene"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/PCC.0b013e3182070990","article-title":"Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis","volume":"12","author":"Checchia","year":"2011","journal-title":"Pediatric Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013757.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"e0176152","DOI":"10.1371\/journal.pone.0176152","article-title":"Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen","volume":"12","author":"Claydon","year":"2017","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"E88","DOI":"10.9778\/cmajo.20180167","article-title":"Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis","volume":"7","author":"Claydon","year":"2019","journal-title":"CMAJ Open"},{"issue":"1-2","key":"10.1002\/14651858.CD013757.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virusres.2011.09.020","article-title":"Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years","volume":"162","author":"Collins","year":"2011","journal-title":"Virus Research"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0048|cit48","unstructured":"Covidence Veritas Health Innovation"},{"issue":"10","key":"10.1002\/14651858.CD013757.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1553-2712.2008.00245.x","article-title":"Prospective multicenter bronchiolitis study: predicting intensive care unit admissions","volume":"15","author":"Damore","year":"2008","journal-title":"Academic Emergency Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/CMR.12.2.298","article-title":"Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment","volume":"12","author":"Domachowske","year":"1999","journal-title":"Clinical Microbiology Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.3390\/vaccines8020201","article-title":"A durable relationship: respiratory syncytial virus bronchiolitis and asthma past their golden anniversary","volume":"8","author":"Esteban","year":"2020","journal-title":"Vaccines"},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40121-017-0151-4","article-title":"The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood","volume":"6","author":"Sim\u00f5es","year":"2017","journal-title":"Infectious Diseases and Therapy"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1164\/rccm.201405-0901PP","article-title":"Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma","volume":"191","author":"Feldman","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2431-10-38","article-title":"A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season","volume":"10","author":"Fern\u00e1ndez","year":"2010","journal-title":"BMC Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD013757.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3390\/ijms18081753","article-title":"New insights contributing to the development of effective vaccines and therapies to reduce the pathology caused by hRSV","volume":"18","author":"G\u00e1lvez","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.201603-0658OC","article-title":"Mortality due to respiratory syncytial virus. Burden and risk factors","volume":"195","author":"Geoghegan","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13584-018-0258-4","article-title":"Should we use palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis","volume":"7","author":"Ginsberg","year":"2018","journal-title":"Israel Journal of Health Policy Research"},{"issue":"14","key":"10.1002\/14651858.CD013757.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1055\/s-0038-1660466","article-title":"Respiratory syncytial virus hospitalizations among U.S. preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016","volume":"35","author":"Goldstein","year":"2018","journal-title":"American Journal of Perinatology"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0059|cit59","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/jinf.2002.1015","article-title":"Respiratory syncytial virus-viral biology and the host response","volume":"45","author":"Hacking","year":"2002","journal-title":"Journal of Infection"},{"issue":"6","key":"10.1002\/14651858.CD013757.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"New England Journal of Medicine."},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1542\/peds.2013-0303","article-title":"Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age","volume":"132","author":"Hall","year":"2013","journal-title":"Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD013757.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"523.e11","DOI":"10.1016\/j.cjca.2010.12.064","article-title":"Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective","volume":"27","author":"Harris","year":"2011","journal-title":"Canadian Journal of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD013757.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s10096-011-1529-y","article-title":"Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis","volume":"31","author":"Herv\u00e1s","year":"2012","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Higgins JP \u00a0Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane 2019 Available from www.training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604.ch8"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0067|cit67","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604"},{"issue":"11","key":"10.1002\/14651858.CD013757.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/oxfordjournals.aje.a115826","article-title":"Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life","volume":"133","author":"Holberg","year":"1991","journal-title":"American Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD013757.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/19420862.2018.1433974","article-title":"Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo","volume":"10","author":"Jacobino","year":"2018","journal-title":"mAbs"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0039-1694008","article-title":"Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the rate, severity, and cost of respiratory syncytial virus hospitalizations among preterm infants","volume":"37","author":"Krilov","year":"2020","journal-title":"American Journal of Perinatology"},{"issue":"6","key":"10.1002\/14651858.CD013757.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.pupt.2013.03.007","article-title":"Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis","volume":"26","author":"La Via","year":"2013","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jmii.2014.08.020","article-title":"Risk factors associated with death in patients with severe respiratory syncytial virus infection","volume":"49","author":"Lee","year":"2016","journal-title":"Journal of Microbiology, Immunology, and Infection"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf MI Cochrane Information Retrieval Methods Group Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604.ch4"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1473-3099(09)70069-6","article-title":"Incubation periods of acute respiratory viral infections: a systematic review","volume":"9","author":"Lessler","year":"2009","journal-title":"Lancet Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"e20184064","DOI":"10.1542\/peds.2018-4064","article-title":"Cost-effectiveness of palivizumab for respiratory syncytial virus: a systematic review","volume":"143","author":"Mac","year":"2019","journal-title":"Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory syncytial virus vaccination during pregnancy and effects in infants","volume":"383","author":"Madhi","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013757.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1542\/peds.2012-0444","article-title":"Prospective multicenter study of children with bronchiolitis requiring mechanical ventilation","volume":"130","author":"Mansbach","year":"2012","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Research Synthesis Methods"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013757.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.jinf.2015.04.025","article-title":"New options in the treatment of respiratory syncytial virus disease","volume":"71","author":"Mejias","year":"2015","journal-title":"Journal of Infection"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1164\/rccm.201609-1812OC","article-title":"Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing. Six-year follow-up study","volume":"196","author":"Mochizuki","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0083|cit83","first-page":"b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Version 2","volume":"339","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jpeds.2019.06.058","article-title":"Effectiveness of palivizumab against respiratory syncytial virus: cohort and case series analysis","volume":"214","author":"Moore","year":"2019","journal-title":"Journal of Pediatrics"},{"issue":"10","key":"10.1002\/14651858.CD013757.pub2-BIB0085|cit85","first-page":"857","article-title":"Substantial variability in community respiratory syncytial virus season timing","volume":"22","author":"Mullins","year":"2003","journal-title":"Pediatric\u00a0Infectious Disease Journal"},{"issue":"9725","key":"10.1002\/14651858.CD013757.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"issue":"9807","key":"10.1002\/14651858.CD013757.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0140-6736(11)61051-9","article-title":"Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis","volume":"378","author":"Nair","year":"2011","journal-title":"Lancet"},{"issue":"9875","key":"10.1002\/14651858.CD013757.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0140-6736(12)61901-1","article-title":"Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis","volume":"381","author":"Nair","year":"2013","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jclinepi.2020.08.008","article-title":"Cochrane Centralised Search Service showed high sensitivity identifying randomized controlled trials: a retrospective analysis","volume":"127","author":"Noel-Storr","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0090|cit90","unstructured":"Noel-Storr A Dooley G Elliott J Steele E Shemilt I Mavergames C An evaluation of Cochrane Crowd found that crowdsourcing produced accurate results in identifying randomized trials Journal of Clinical Epidemiology 10.1016\/j.jclinepi.2021.01.006"},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"020431","DOI":"10.7189\/jogh.09.020431","article-title":"Respiratory syncytial virus in the Western Pacific Region: a systematic review and meta-analysis","volume":"9","author":"Pangesti","year":"2019","journal-title":"Journal of Global Health"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00019053-200422050-00001","article-title":"Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases","volume":"22","author":"Paramore","year":"2004","journal-title":"PharmacoEconomics"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/01.inf.0000126273.27123.33","article-title":"Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002","volume":"23","author":"Purcell","year":"2004","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0094|cit94","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"issue":"9","key":"10.1002\/14651858.CD013757.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1128\/AAC.06446-11","article-title":"Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children","volume":"56","author":"Robbie","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"7","key":"10.1002\/14651858.CD013757.pub2-BIB0096|cit96","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007743.pub6","article-title":"Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis","author":"Robinson","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013757.pub2-BIB0097|cit97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009417.pub2","article-title":"Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection","author":"Sanders","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1183\/09031936.02.00019902","article-title":"RSV bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life","volume":"20","author":"Schauer","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD013757.pub2-BIB0099|cit99","first-page":"e984","article-title":"Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series","volume":"5","author":"Scheltema","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD013757.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S2213-2600(18)30055-9","article-title":"Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial","volume":"6","author":"Scheltema","year":"2018","journal-title":"Lancet Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13561-017-0181-3","article-title":"Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain","volume":"7","author":"Schmidt","year":"2017","journal-title":"Health Economics Review"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/317655","article-title":"Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997","volume":"183","author":"Shay","year":"2001","journal-title":"Journal of Infectious Diseases"},{"issue":"10098","key":"10.1002\/14651858.CD013757.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.200406-730OC","article-title":"Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13","volume":"171","author":"Sigurs","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaci.2010.05.026","article-title":"The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children","volume":"126","author":"Sim\u00f5es","year":"2010","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40121-018-0188-z","article-title":"Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children","volume":"7","author":"Sim\u00f5es","year":"2018","journal-title":"Infectious Diseases and Therapy"},{"issue":"8","key":"10.1002\/14651858.CD013757.pub2-BIB0107|cit107","first-page":"1256","article-title":"Long-term assessment of healthcare utilization 5 years after respiratory syncytial virus infection in US infants","volume":"221","author":"Sim\u00f5es","year":"2020","journal-title":"Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1164\/rccm.200603-435PP","article-title":"Bronchiolitis to asthma: a review and call for studies of gene-virus interactions in asthma causation","volume":"175","author":"Singh","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s10020-020-00162-6","article-title":"Antibody development for preventing the human respiratory syncytial virus pathology","volume":"26","author":"Soto","year":"2020","journal-title":"Molecular Medicine"},{"issue":"9178","key":"10.1002\/14651858.CD013757.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(98)10321-5","article-title":"Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years","volume":"354","author":"Stein","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0112|cit112","unstructured":"SYNAGIS \u00ae (palivizumab) www.ema.europa.eu\/en\/medicines\/human\/EPAR\/synagis#overview-section"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0113|cit113","unstructured":"Thomas J McDonald S Noel-Storr A Shemilt I Elliott J Mavergames C Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane Reviews Journal of Clinical Epidemiology 10.1016\/j.jclinepi.2020.11.003"},{"issue":"12","key":"10.1002\/14651858.CD013757.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1164\/rccm.200809-1471OC","article-title":"Exploring the association between severe respiratory syncytial virus infection and asthma: a registry-based twin study","volume":"179","author":"Thomsen","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/adc.2008.139188","article-title":"Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection","volume":"94","author":"Thorburn","year":"2009","journal-title":"Archives of Disease in Childhood"},{"issue":"3","key":"10.1002\/14651858.CD013757.pub2-BIB0116|cit116","first-page":"e01302","article-title":"Respiratory syncytial virus: targeting the G protein provides a new approach for an old problem","volume":"92","author":"Tripp","year":"2017","journal-title":"Journal of Virology"},{"issue":"12","key":"10.1002\/14651858.CD013757.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/jpc.14083","article-title":"Improving the prescribing of palivizumab","volume":"54","author":"Trist","year":"2018","journal-title":"Journal of Paediatrics and Child Health"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3310\/hta12360","article-title":"Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation","volume":"12","author":"Wang","year":"2008","journal-title":"Health Technology Assessment"},{"issue":"2","key":"10.1002\/14651858.CD013757.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40121-014-0046-6","article-title":"Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review","volume":"3","author":"Wegzyn","year":"2014","journal-title":"Infectious Diseases and Therapy"},{"issue":"9","key":"10.1002\/14651858.CD013757.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1185\/03007995.2010.505126","article-title":"Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children","volume":"26","author":"Checchia","year":"2010","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0121|cit121","unstructured":"World Health Organization World Health Statistics 2018: monitoring health for the SDGs www.who.int\/gho\/publications\/world_health_statistics\/2018\/en\/"},{"issue":"5","key":"10.1002\/14651858.CD013757.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1542\/peds.2013-0982","article-title":"Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants","volume":"132","author":"Yoshihara","year":"2013","journal-title":"Pediatrics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013757.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1053\/rmed.2002.1298","article-title":"Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants","volume":"96","author":"Young","year":"2002","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jpeds.2019.02.020","article-title":"Impact of American Academy of Pediatrics palivizumab guidance for children \u2265 29 and < 35 weeks of gestational age","volume":"209","author":"Zembles","year":"2019","journal-title":"Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD013757.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"010408","DOI":"10.7189\/jogh.06.010408","article-title":"Cost of management of severe pneumonia in young children: systematic analysis","volume":"6","author":"Zhang","year":"2016","journal-title":"Journal of Global Health"},{"issue":"388","key":"10.1002\/14651858.CD013757.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Science Translational Medicine"},{"key":"10.1002\/14651858.CD013757.pub2-BIB0127|cit127","unstructured":"Palivizumab for preventing respiratory syncytial virus (RSV) infection in children Cochrane Database of Systematic Reviews 2020 10 10.1002\/14651858.CD013757"}],"updated-by":[{"DOI":"10.1002\/14651858.cd013757.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T09:18:08Z","timestamp":1749460688000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013757.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Acute Respiratory Infections Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":127,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013757.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]}}}